Optimizing Continuous Renal Replacement Therapy with Regional Citrate Anticoagulation: Insights from the ORCA Trial—A Retrospective Study on 10 Years of Practice

Optimizing Continuous Renal Replacement Therapy with Regional Citrate Anticoagulation: Insights from the ORCA Trial—A Retrospective Study on 10 Years of Practice

(1) Background: Citrate is preferred in continuous renal replacement therapy (CRRT) for critically ill patients because it prolongs filter life and reduces bleeding risks compared to unfractionated heparin (UFH). However, regional citrate anticoagulation (RCA) can lead to acid–base disturbances, cit...

Descripció completa

Dades bibliogràfiques
Autors principals: Rita Jacobs, Walter Verbrugghe, Jason Bouziotis, Ingrid Baar, Karolien Dams, Annick De Weerdt, Philippe G. Jorens
Format: Article
Idioma:English
Publicat: MDPI AG 2024-10-01
Col·lecció:Life
Matèries:
citrate anticoagulation
heparin
renal replacement therapy
filter lifespan
bleeding
acid–base disturbances
Accés en línia:https://www.mdpi.com/2075-1729/14/10/1304

Internet

https://www.mdpi.com/2075-1729/14/10/1304

Ítems similars